Epigenomics AG (EPGNF)

Epigenomics AG (EPGNF) Healthcare & Pipeline Overview

Epigenomics AG is a pioneering molecular diagnostics firm focused on liquid biopsy technology for early cancer detection, with its flagship product, Epi proColon, leading the market in non-invasive colorectal cancer screening.

What Is the Investment Thesis for EPGNF?

Epigenomics AG presents a unique investment thesis driven by its innovative product offerings and the growing demand for non-invasive cancer screening methods. The company's lead product, Epi proColon, is positioned in a market projected to grow significantly as awareness of colorectal cancer screening increases. With a gross margin of 75.3%, Epigenomics demonstrates strong operational efficiency, although it currently faces challenges reflected in a profit margin of -2479.2%. The ongoing development of additional diagnostic tests and potential partnerships with healthcare providers could serve as catalysts for revenue growth. Furthermore, the increasing incidence of colorectal cancer globally, coupled with rising healthcare expenditures, underscores the potential for Epigenomics to capture a larger market share. However, investors should remain cautious of the company's financial health and the competitive landscape, particularly as new entrants emerge in the liquid biopsy space.

Based on FMP financials and quantitative analysis

EPGNF Key Highlights

• Market Cap: $0.00B, indicating a low valuation relative to potential market opportunities.
• Gross Margin of 75.3%, showcasing strong profitability on product sales.
• Profit Margin of -2479.2%, highlighting significant operational challenges.
• Beta of 0.98, suggesting lower volatility compared to the broader market.
• No dividend yield, as the company is focused on reinvesting in growth initiatives.

Who Are EPGNF's Competitors?

EPGNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EPGNF's Key Strengths?

• Innovative product offerings in liquid biopsy technology.
• Strong gross margins indicating operational efficiency.
• Established patents protecting proprietary technology.
• Focus on a growing market for early cancer detection.

What Are EPGNF's Weaknesses?

• High negative profit margin indicating financial challenges.
• Limited employee base may restrict operational scalability.
• Dependence on a few key products for revenue generation.
• Relatively low market capitalization limits growth potential.

What Could Drive EPGNF Stock Higher?

• Potential regulatory approvals for new diagnostic tests in the next 12 months.
• Continued market penetration of Epi proColon in the U.S. and European markets.
• Ongoing research and development activities aimed at expanding product offerings.
• Strategic partnerships with healthcare providers anticipated to be announced within the year.
• Increasing awareness and demand for non-invasive cancer screening solutions.

What Are the Key Risks for EPGNF?

• Financial-distress signal — its Altman Z-Score of -10.46 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-74.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles may delay product launches and market entry.
• Intense competition from established players in the diagnostics space.
• Financial instability due to high negative profit margins.
• Market volatility affecting stock performance and investor confidence.

What Are the Growth Opportunities for EPGNF?

• Expansion in the U.S. Market: The U.S. colorectal cancer screening market is projected to grow significantly, with a focus on increasing awareness and adoption of non-invasive tests like Epi proColon. As healthcare providers seek to improve screening rates, Epigenomics is well-positioned to capture market share, particularly among patients hesitant to undergo traditional colonoscopies. This opportunity could lead to substantial revenue growth over the next five years.
• International Market Penetration: Epigenomics AG aims to expand its presence in Europe and China, where the demand for early cancer detection is rising. The global liquid biopsy market is expected to reach $5 billion by 2027, and Epigenomics can leverage its existing products to tap into these lucrative markets, potentially doubling its revenue by 2028.
• Technological Advancements: Continuous investment in research and development will enable Epigenomics to innovate and introduce new diagnostic tests. By identifying novel biomarkers and developing additional liquid biopsy tests, the company can diversify its product portfolio and cater to a broader range of cancers, enhancing its competitive edge in the diagnostics market.
• Strategic Partnerships: Collaborating with healthcare providers and research institutions can enhance Epigenomics' market reach and credibility. Such partnerships may facilitate clinical trials and increase product adoption rates, leading to accelerated revenue growth and improved market positioning.
• Regulatory Approvals: Securing regulatory approvals for new products can serve as a significant growth catalyst. As Epigenomics continues to innovate, obtaining necessary certifications will enable the company to launch its products in new markets, driving sales and enhancing brand recognition.

What Opportunities Does EPGNF Have?

• Expanding market for liquid biopsy tests as awareness grows.
• Potential partnerships with healthcare providers for wider distribution.
• Increasing demand for non-invasive cancer screening solutions.
• Possibility of entering new geographic markets to drive sales.

What Threats Does EPGNF Face?

• Intense competition from established diagnostic companies.
• Regulatory hurdles may delay product approvals.
• Market volatility affecting investor sentiment and funding.
• Rapid technological advancements could outpace company innovations.

What Are EPGNF's Competitive Advantages?

• Strong intellectual property portfolio with patented diagnostic tests.
• Expertise in liquid biopsy technology differentiates from competitors.
• Established relationships with healthcare providers enhance market access.
• Focus on early cancer detection aligns with increasing healthcare demands.
• Limited competition in the niche of blood-based colorectal cancer screening.

What Does EPGNF Do?

Epigenomics AG, founded in 1998, is a molecular diagnostics company headquartered in Heidelberg, Germany. The company specializes in liquid biopsy technology aimed at the early detection of cancer, with a particular focus on colorectal cancer. Its flagship product, Epi proColon, is a blood-based test designed to detect colorectal cancer in patients across the United States, Europe, and China. In addition to Epi proColon, Epigenomics offers a hepatocellular carcinoma blood test and Epi BiSKit, a pre-analytical tool that provides reagents for the preparation of bisulfite-converted DNA. The company's research and development efforts are dedicated to identifying suitable biomarkers in human tissue and developing corresponding in vitro diagnostic blood tests, which are patented to protect their innovations. Despite being a small company with only six employees, Epigenomics AG has carved out a niche in the rapidly growing field of molecular diagnostics, leveraging its expertise to address the critical need for early cancer detection, which is essential for improving patient outcomes and reducing healthcare costs associated with late-stage cancer treatments.

What Products and Services Does EPGNF Offer?

• Develops molecular diagnostics for early cancer detection.
• Offers blood-based tests, including Epi proColon for colorectal cancer.
• Provides a hepatocellular carcinoma blood test.
• Supplies Epi BiSKit, a pre-analytical tool for DNA preparation.
• Conducts research to identify biomarkers for in vitro diagnostic tests.
• Focuses on liquid biopsy technology to improve patient outcomes.

How Does EPGNF Make Money?

• Generates revenue through the sale of diagnostic tests.
• Engages in research and development to create innovative products.
• Licenses technology and patents to other healthcare entities.
• Collaborates with healthcare providers for product distribution.
• Seeks funding through grants and partnerships for R&D initiatives.

What Industry Does EPGNF Operate In?

The molecular diagnostics industry is experiencing rapid growth, driven by advancements in technology and an increasing emphasis on early cancer detection. The global market for liquid biopsy is expected to expand significantly, with estimates suggesting a CAGR of over 20% in the coming years. Epigenomics AG operates within this dynamic landscape, competing with established players and emerging startups. The demand for non-invasive testing solutions is being fueled by rising cancer incidence rates and a shift towards personalized medicine, positioning Epigenomics to capitalize on these trends as it continues to innovate and expand its product offerings.

Who Are EPGNF's Key Customers?

• Healthcare providers seeking non-invasive cancer screening solutions.
• Patients looking for early detection options for colorectal cancer.
• Research institutions interested in molecular diagnostics technology.
• Laboratories requiring reagents for DNA preparation.
• Oncologists and specialists focusing on early cancer intervention.

Company Profile

Epigenomics AG operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Heidelberg, DE. The company is led by CEO Noel Thomas Doheny. EPGNF has traded publicly since 2010.

F-Score 2/9Financial Health

Epigenomics AG's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.46 places it in the distress zone, a signal of elevated financial risk.

ROE -74%Key Financial Metrics

Return on equity for Epigenomics AG stands at -74.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -75.9%, showing how much profit it generates from its asset base. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations.

EPGNF Valuation & Market Position

With a 982K market cap, Epigenomics AG sits in the micro-cap segment of the market. Relative to its peer group, EPGNF's quantitative score of 55/100 is roughly in line with the peer average of 60/100.

EPGNF Financials

EPGNF Latest News

No recent news available for EPGNF.

EPGNF Analyst Consensus

EPGNF MoonshotScore

Common Questions About EPGNF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources